Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 12/20 | 0.86 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306229 | 0.85 | BAZ2B (0.86) | BAZ2BKDRMAPTLMNAMEN1 | |
| SCHEMBL10127727 | 0.84 | BAZ2B (0.62) | BAZ2BKDRMAPTLMNAALDH1A1 | |
| SCHEMBL29171353 | 0.81 | BAZ2B (0.79) | BAZ2BMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL620113 | 0.81 | BAZ2B (0.58) | BAZ2BKDRMAPTLMNAALDH1A1 | |
| SCHEMBL10127679 | 0.81 | BAZ2B (0.60) | BAZ2BALOX15HSD17B10 | |
| SCHEMBL14015613 | 0.80 | BAZ2B (0.77) | BAZ2BMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL12868355 | 0.79 | BAZ2B (1.00) | BAZ2BKDRMAPTLMNAALDH1A1 | |
| SCHEMBL10777655 | 0.78 | SMN1; SMN2 (0.79) | BAZ2BMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL5104575 | 0.77 | BAZ2B (0.71) | BAZ2BMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL620055 | 0.76 | BAZ2B (0.55) | BAZ2BKDRMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | IVASHCHENKO ANDREY ALEXANDROVICH | 2011-02-24 | — | — | US | disclosed |
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | IVASHCHENKO ANDREY ALEXANDROVICH | 2011-02-24 | — | — | US | disclosed |
| EP-2184064-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2062895-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008060190-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008024029-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ABCG2, HTR3C, AADAC | BAZ2B 428/4885KDR 2394/4885MAPT 4749/4885 |
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | HTR6, HTR1A, HTR3B | BAZ2B 4245/4885KDR 339/4885MAPT 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.